SAN ANTONIO, TX and HAYWARD, CA – October 31, 2018– Paragon Genomics, Inc., a leader in amplicon-based target enrichment and library preparation solutions for next-generation sequencing (NGS) assays today announced a partnership with SOPHiA GENETICS designed to accelerate the global adoption of Data-Driven Medicine worldwide. Under the terms of the agreement, Paragon Genomics’ CleanPlex® NGStarget enrichment technologies will be incorporated in the SOPHiA AI Platform. The partnership is being announced at the Association for Molecular Pathology 2018 Annual Meeting (AMP 2018).
Paragon Genomics’ CleanPlex is a proprietary, ultra-high multiplexed NGS target enrichment technology that allows a large number of targets to be interrogated rapidly and accurately using a streamlined workflow with superior analytical performance. The CleanPlex technology is provided as ready-to-use and custom NGS panels and is available for use with Illumina or Ion Torrent platforms. CleanPlex will now also be incorporated in the SOPHiA AI Platform, providing a comprehensive and standardized solution for accurate genomic detection and characterization of all types of tumor alterations in a single test.
Tao Chen, co-founder and CEO of Paragon Genomics, said, “This partnership with SOPHiA GENETICS greatly expands the universe of cancer experts able to benefit from our proprietary CleanPlex target enrichment technologies. The best-in-class SOPHiA AI technology currently reaches a large and growing global community of hospitals and laboratories, which use its universal platform to achieve exceptional analytical performance. The worldwide launch of this partnership will provide immediate access to our combined solutions, enabling these providers to more rapidly and precisely identify tumor mutations and improve the throughput, quality and reliability of their sequencing results.”
Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS, commented, “This new partnership reflects our ongoing commitment to provide our global community of healthcare institutions with the most effective genomic solutions available, thereby accelerating the adoption of Data-Driven Medicine. Paragon technology has proven to be a very solid Amplicon-based technology that will definitively benefit to users of our SOPHiA AI Platform for Oncology applications.”